

1. Modeli B. Global epidemiology of hemoglobin disorders and derived service indicators. *Bull World Health Organ.* 2008;86(6):480–487.
2. Loukopoulou D. Haemoglobinopathies. 2002;1–10.
3. Rachmilowitz EA, Giardina PJ. How I treat thalassemia. *Blood.* 2011;118(13):3479–88.
4. The premaral source for medical images [Internet]. esliverimages.com.
5. Dong A, Rivella S, Breda L. Gene therapy for hemoglobinopathies: progress and challenges. *Nat Rev Clin Oncol.* 2013;11(6):293–306. <http://www.nature.com/nrclinonc>.
6. Tischenchtein T, Perez-Janez N, Escors D. Lentiviral vectors for cancer immunotherapy and clinical applications. *Cancers (Basel).* 2013;5(3):815–37.
7. Arumugam PJ, Scholes J, Perelman N, Xia R, Yee J-K, Malik P. Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site 1 (cHS4) splice enhancer. *Mol Ther.* 2007;15(10):1863–71.
8. Kalle C, von Baum C, Williams DA. Lent in red: progress in gene therapy for human hemoglobinopathies. *Clin Invest (Lond).* 2004;114(7):889–89.
9. Elmer GW. The use of chromatin lentiviruses to improve the expression and safety of integrating gene transfer vectors. *Hum Gene Ther.* 2011;22(9):761–74.